{"result": "\n{\n    \"title\": \"Septic Shock Clinical Trials: Placebo and Hydrocortisone Groups\",\n    \"summary\": \"The community is centered around clinical trials investigating treatments for septic shock, with a focus on the Placebo Group and the Hydrocortisone Group. These trials aim to evaluate the efficacy and safety of hydrocortisone and other treatments by comparing them to a placebo. The trials involve multiple countries and include assessments of various health outcomes and adverse events.\",\n    \"rating\": 8.5,\n    \"rating_explanation\": \"The impact severity rating is high due to the critical nature of septic shock treatment and the potential implications for patient outcomes and clinical practices.\",\n    \"findings\": [\n        {\n            \"summary\": \"Role of the Placebo Group in Clinical Trials\",\n            \"explanation\": \"The Placebo Group serves as a control in the clinical trials for septic shock, providing a baseline for evaluating the efficacy of active treatments like hydrocortisone. This group is crucial for understanding the true impact of these treatments on outcomes such as 90-day mortality and other health metrics. The Placebo Group was involved in various studies, including those assessing severe sepsis and the effects of Drotrecogin Alfa Activated [Data: Entities (61); Relationships (158, 275, 280, 279, 270)].\"\n        },\n        {\n            \"summary\": \"Hydrocortisone Group's Impact on Septic Shock Treatment\",\n            \"explanation\": \"The Hydrocortisone Group is a key component of the trials, designed to assess the effects of hydrocortisone on patients with septic shock. This group consistently received hydrocortisone, and the trials aimed to determine its impact on patient outcomes, including ICU discharge times and reversal of shock. The group experienced a higher percentage of adverse events compared to the Placebo Group, highlighting the need for careful evaluation of treatment risks and benefits [Data: Entities (558); Relationships (157, 336, 993, 825, 284)].\"\n        },\n        {\n            \"summary\": \"Adverse Events Monitoring and Analysis\",\n            \"explanation\": \"Adverse events were a significant focus in the trials, with a range of unintended and harmful occurrences being closely monitored. These events included arrhythmias, myocardial necrosis, and secondary infections, with a higher percentage reported in the Hydrocortisone Group. The monitoring and categorization of these events were crucial for safety assessments and informed the evaluation of treatment efficacy [Data: Entities (334); Relationships (499, 825, 286, 532)].\"\n        },\n        {\n            \"summary\": \"Corticotropin Testing in Septic Shock Trials\",\n            \"explanation\": \"Corticotropin was used in the trials to evaluate adrenal function in patients with septic shock. This hormone testing provided critical insights into adrenal responsiveness and patient response, contributing to a better understanding of treatment impacts. The trials included assessments of both responders and nonresponders to corticotropin, offering valuable data for tailoring treatment approaches [Data: Entities (601); Relationships (164, 292, 992)].\"\n        },\n        {\n            \"summary\": \"International Scope of the Clinical Trials\",\n            \"explanation\": \"The clinical trials for septic shock treatments were conducted across multiple countries, including Denmark, Australia, New Zealand, and the United Kingdom. This international scope allowed for a diverse patient population and enhanced the generalizability of the study findings. The involvement of various countries also facilitated collaboration and knowledge sharing among medical institutions [Data: Entities (106); Relationships (78, 88, 281, 77, 87, 770, 464)].\"\n        }\n    ]\n}", "input": "\nYou are an AI assistant that helps a human analyst to perform general information discovery. Information discovery is the process of identifying and assessing relevant information associated with certain entities (e.g., organizations and individuals) within a network.\n\n# Goal\nWrite a comprehensive report of a community, given a list of entities that belong to the community as well as their relationships and optional associated claims. The report will be used to inform decision-makers about information associated with the community and their potential impact. The content of this report includes an overview of the community's key entities, their legal compliance, technical capabilities, reputation, and noteworthy claims.\n\n# Report Structure\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\n\n# Example Input\n-----------\nText:\n\nEntities\n\nid,entity,description\n5,VERDANT OASIS PLAZA,Verdant Oasis Plaza is the location of the Unity March\n6,HARMONY ASSEMBLY,Harmony Assembly is an organization that is holding a march at Verdant Oasis Plaza\n\nRelationships\n\nid,source,target,description\n37,VERDANT OASIS PLAZA,UNITY MARCH,Verdant Oasis Plaza is the location of the Unity March\n38,VERDANT OASIS PLAZA,HARMONY ASSEMBLY,Harmony Assembly is holding a march at Verdant Oasis Plaza\n39,VERDANT OASIS PLAZA,UNITY MARCH,The Unity March is taking place at Verdant Oasis Plaza\n40,VERDANT OASIS PLAZA,TRIBUNE SPOTLIGHT,Tribune Spotlight is reporting on the Unity march taking place at Verdant Oasis Plaza\n41,VERDANT OASIS PLAZA,BAILEY ASADI,Bailey Asadi is speaking at Verdant Oasis Plaza about the march\n43,HARMONY ASSEMBLY,UNITY MARCH,Harmony Assembly is organizing the Unity March\n\nOutput:\n{{\n    \"title\": \"Verdant Oasis Plaza and Unity March\",\n    \"summary\": \"The community revolves around the Verdant Oasis Plaza, which is the location of the Unity March. The plaza has relationships with the Harmony Assembly, Unity March, and Tribune Spotlight, all of which are associated with the march event.\",\n    \"rating\": 5.0,\n    \"rating_explanation\": \"The impact severity rating is moderate due to the potential for unrest or conflict during the Unity March.\",\n    \"findings\": [\n        {{\n            \"summary\": \"Verdant Oasis Plaza as the central location\",\n            \"explanation\": \"Verdant Oasis Plaza is the central entity in this community, serving as the location for the Unity March. This plaza is the common link between all other entities, suggesting its significance in the community. The plaza's association with the march could potentially lead to issues such as public disorder or conflict, depending on the nature of the march and the reactions it provokes. [Data: Entities (5), Relationships (37, 38, 39, 40, 41,+more)]\"\n        }},\n        {{\n            \"summary\": \"Harmony Assembly's role in the community\",\n            \"explanation\": \"Harmony Assembly is another key entity in this community, being the organizer of the march at Verdant Oasis Plaza. The nature of Harmony Assembly and its march could be a potential source of threat, depending on their objectives and the reactions they provoke. The relationship between Harmony Assembly and the plaza is crucial in understanding the dynamics of this community. [Data: Entities(6), Relationships (38, 43)]\"\n        }},\n        {{\n            \"summary\": \"Unity March as a significant event\",\n            \"explanation\": \"The Unity March is a significant event taking place at Verdant Oasis Plaza. This event is a key factor in the community's dynamics and could be a potential source of threat, depending on the nature of the march and the reactions it provokes. The relationship between the march and the plaza is crucial in understanding the dynamics of this community. [Data: Relationships (39)]\"\n        }},\n        {{\n            \"summary\": \"Role of Tribune Spotlight\",\n            \"explanation\": \"Tribune Spotlight is reporting on the Unity March taking place in Verdant Oasis Plaza. This suggests that the event has attracted media attention, which could amplify its impact on the community. The role of Tribune Spotlight could be significant in shaping public perception of the event and the entities involved. [Data: Relationships (40)]\"\n        }}\n    ]\n}}\n\n\n# Real Data\n\nUse the following text for your answer. Do not make anything up in your answer.\n\nText:\n-----Entities-----\nhuman_readable_id,title,description,degree\n61,PLACEBO GROUP,\"The PLACEBO GROUP in the study is a control group consisting of patients who received a placebo treatment. This group serves as a comparison to evaluate the effects of various active treatments being tested in the trial. Specifically, the placebo group did not receive treatments such as Drotrecogin Alfa Activated, cisatracurium, or hydrocortisone-plus-fludrocortisone. Instead, they were given a placebo to provide a baseline for assessing the efficacy and safety of these active treatments. The placebo group is crucial for determining the true impact of the active treatments on outcomes such as 90-day mortality and other health metrics.\",35\n558,HYDROCORTISONE GROUP,\"The \"\"HYDROCORTISONE GROUP\"\" refers to a group of patients in a study who were assigned to receive hydrocortisone treatment. This group was part of a trial designed to assess the effects of hydrocortisone on patients with septic shock. Throughout the study, these patients consistently received hydrocortisone as part of the study regimen.\",22\n601,CORTICOTROPIN,\"Corticotropin is a hormone used in tests to evaluate adrenal function, particularly in patients with septic shock. It is utilized in studies to assess patient response and adrenal responsiveness, providing critical insights into adrenal function during such medical evaluations.\",4\n97,CISATRACURIUM GROUP,\"The CISATRACURIUM GROUP refers to the group of patients in the study who received cisatracurium, a neuromuscular blocking agent, as part of their treatment.\",4\n334,ADVERSE EVENTS,\"The adverse events in the trial encompassed a range of unintended and harmful occurrences, which were closely monitored for safety assessment. These events included arrhythmias, myocardial necrosis, skin necrosis, ischemia, and secondary infections. Notably, a higher percentage of these adverse events were reported in the hydrocortisone group.\",5\n106,DENMARK,\"Denmark is one of the countries where multiple clinical trials were conducted, including the ADRENAL and TRISS trials. The country participated with at least one medical-surgical ICU site involved in these research efforts.\",5\n612,ANNANE STUDY,\"The ANNANE STUDY is a research investigation that explored the use of etomidate for the induction of anesthesia in critically ill patients. Additionally, the study reported findings on improved survival rates and the reversal of shock in patients who did not respond to corticotropin. These patients benefited from the administration of hydrocortisone combined with fludrocortisone.\",4\n600,CLINICAL EVALUATION COMMITTEE,\"The CLINICAL EVALUATION COMMITTEE was a committee responsible for assessing the appropriateness of antiinfective treatments in the CORTICUS study. The committee operated without knowledge of the study-group assignments to ensure unbiased evaluations. Additionally, the committee determined the appropriateness of antimicrobial therapy for patients participating in the study, ensuring that treatments were suitable and effective for the study's objectives.\",3\n405,ETOMIDATE,\"Etomidate is a medication that was administered to some patients before randomization in the study. It was used particularly before study entry. However, it is important to note that Etomidate is associated with a higher risk for Critical Illness-Related Corticosteroid Insufficiency (CIRCI) and increased mortality in patients with septic shock.\",3\n562,BLOOD TRANSFUSION,\"The process of transferring blood or blood products into one's circulation intravenously, which was less frequent in the hydrocortisone group\",2\n101,COX REGRESSION MODEL,,2\n563,NEW-ONSET BACTEREMIA,\"The presence of bacteria in the blood, which was tracked as an outcome in the trial\",2\n564,NEW-ONSET FUNGEMIA,\"The presence of fungi in the blood, which was tracked as an outcome in the trial\",2\n63,SAFETY MONITORING BOARD,The safety monitoring board is an independent group of experts that monitors patient safety and treatment efficacy data while a clinical trial is ongoing,2\n611,REVERSAL OF SHOCK,The event of patients recovering from shock during the study,2\n\n\n-----Relationships-----\nhuman_readable_id,source,target,description,rank\n158,SEPTIC SHOCK,PLACEBO GROUP,The placebo group was involved in a clinical trial designed to evaluate the effects of a treatment on septic shock. This group was specifically studied to understand the impact of the treatment by comparing it to the effects observed in patients with septic shock who did not receive the active treatment.,105\n157,SEPTIC SHOCK,HYDROCORTISONE GROUP,The hydrocortisone group was involved in a trial designed to evaluate the treatment effects on septic shock. This group was specifically studied to assess how hydrocortisone impacts the condition of septic shock.,92\n275,PLACEBO GROUP,ICU,The PLACEBO GROUP consisted of patients who were treated in the ICU. These patients experienced a longer time to ICU discharge compared to those in the hydrocortisone group.,81\n285,PLACEBO GROUP,TRIAL,The placebo group was a part of the trial,75\n164,SEPTIC SHOCK,CORTICOTROPIN,Corticotropin testing was used to assess adrenal function in patients with septic shock,74\n336,ICU,HYDROCORTISONE GROUP,Patients in the hydrocortisone group had a shorter time to ICU discharge,68\n501,TRIAL,HYDROCORTISONE GROUP,The hydrocortisone group was a part of the trial,62\n284,PLACEBO GROUP,HYDROCORTISONE GROUP,The PLACEBO GROUP and the HYDROCORTISONE GROUP were both part of the same clinical trial designed to compare the effects of hydrocortisone and placebo. This study specifically focused on assessing the effectiveness of hydrocortisone in patients with septic shock by comparing outcomes between the two groups.,57\n280,PLACEBO GROUP,SEVERE SEPSIS,The Placebo Group served as a control in the study of severe sepsis.,52\n278,PLACEBO GROUP,SUPPLEMENTARY APPENDIX,The Supplementary Appendix contains additional data and figures related to the placebo group,51\n306,ICU,CISATRACURIUM GROUP,Patients in the cisatracurium group were treated in the ICU,50\n279,PLACEBO GROUP,DROTRECOGIN ALFA ACTIVATED,\"In a study aimed at evaluating the efficacy of Drotrecogin Alfa Activated in treating severe sepsis, Drotrecogin Alfa Activated was compared to a placebo group. The research focused on assessing the effects of Drotrecogin Alfa Activated in patients suffering from severe sepsis, providing insights into its potential benefits over a placebo.\",50\n273,PLACEBO GROUP,CISATRACURIUM,The study compares the effects of cisatracurium on 90-day mortality against a placebo group,48\n78,AUSTRALIA,PLACEBO GROUP,Australia was one of the countries where patients were enrolled in the placebo group,48\n88,NEW ZEALAND,PLACEBO GROUP,New Zealand was one of the countries where patients were enrolled in the placebo group,46\n499,TRIAL,ADVERSE EVENTS,Adverse events were monitored and categorized during the trial,45\n119,APACHE II SCORE,PLACEBO GROUP,APACHE II scores were used to assess the severity of patients in the placebo group,43\n270,PLACEBO GROUP,SEVERE SEPSIS STUDY,The placebo group is a part of the severe sepsis study,42\n287,PLACEBO GROUP,MECHANICAL VENTILATION,Patients in the placebo group had a longer duration of the initial episode of mechanical ventilation compared to the hydrocortisone group,42\n289,PLACEBO GROUP,RENAL-REPLACEMENT THERAPY,The rate of use of renal-replacement therapy was monitored in the placebo group,42\n268,PLACEBO GROUP,CORTICOSTEROID GROUP,\"The PLACEBO GROUP and CORTICOSTEROID GROUP are the two comparison groups involved in a clinical trial designed to evaluate the effects of corticosteroids against a placebo. Both groups are part of a study focused on severe sepsis, with the placebo group serving as a control to assess the impact of corticosteroid therapy.\",41\n281,PLACEBO GROUP,UNITED KINGDOM,The United Kingdom was one of the countries where patients were enrolled in the placebo group,41\n286,PLACEBO GROUP,ADVERSE EVENTS,The placebo group experienced fewer adverse events compared to the hydrocortisone group,40\n283,PLACEBO GROUP,DENMARK,Denmark was one of the countries where patients were enrolled in the placebo group,40\n282,PLACEBO GROUP,SAUDI ARABIA,Saudi Arabia was one of the countries where patients were enrolled in the placebo group,40\n295,PLACEBO GROUP,ANNANE STUDY,The Annane study reported a higher rate of death in the placebo group compared to the current study,39\n274,PLACEBO GROUP,CISATRACURIUM GROUP,The study involved a comparison between the PLACEBO GROUP and the CISATRACURIUM GROUP to evaluate the effectiveness of the treatment. It specifically compared the outcomes of patients receiving cisatracurium with those receiving a placebo.,39\n292,PLACEBO GROUP,CORTICOTROPIN,The placebo group in the study included patients who both did and did not respond to corticotropin. The response of the placebo group to corticotropin was assessed as part of the study.,39\n297,PLACEBO GROUP,HYDROCORTISONE-PLUS-FLUDROCORTISONE TRIAL,The trial involved a group of patients receiving a placebo for comparison,39\n296,PLACEBO GROUP,CLINICAL EVALUATION COMMITTEE,The committee evaluated the appropriateness of antimicrobial therapy for the placebo group,38\n293,PLACEBO GROUP,ETOMIDATE,The PLACEBO GROUP included some patients who received ETOMIDATE before study entry and prior to randomization.,38\n288,PLACEBO GROUP,BLOOD TRANSFUSION,More patients in the placebo group received a blood transfusion compared to the hydrocortisone group,37\n277,PLACEBO GROUP,COX REGRESSION MODEL,The Cox regression model was used to analyze the hazard ratio for death in the placebo group,37\n290,PLACEBO GROUP,NEW-ONSET BACTEREMIA,The rate of new-onset bacteremia was tracked in the placebo group,37\n291,PLACEBO GROUP,NEW-ONSET FUNGEMIA,The rate of new-onset fungemia was tracked in the placebo group,37\n269,PLACEBO GROUP,SAFETY MONITORING BOARD,The safety monitoring board oversees the safety and efficacy of treatments in the placebo group during the clinical trial,37\n271,PLACEBO GROUP,NONRESPONDERS,Nonresponders include patients from the placebo group,37\n272,PLACEBO GROUP,RESPONDERS,Responders include patients from the placebo group,37\n276,PLACEBO GROUP,PNEUMOTHORAX,Pneumothorax occurred more frequently in the placebo group compared to the cisatracurium group,37\n294,PLACEBO GROUP,REVERSAL OF SHOCK,Patients in the placebo group experienced a longer time to reversal of shock compared to the hydrocortisone group,37\n298,PLACEBO GROUP,HYDROCORTISONE-PLUS-FLUDROCORTISONE GROUP,The trial compared outcomes between the hydrocortisone-plus-fludrocortisone group and the placebo group,37\n77,AUSTRALIA,HYDROCORTISONE GROUP,Australia was one of the countries where patients were enrolled in the hydrocortisone group,35\n87,NEW ZEALAND,HYDROCORTISONE GROUP,New Zealand was one of the countries where patients were enrolled in the hydrocortisone group,33\n118,APACHE II SCORE,HYDROCORTISONE GROUP,APACHE II scores were used to assess the severity of patients in the hydrocortisone group,30\n600,MECHANICAL VENTILATION,HYDROCORTISONE GROUP,Patients in the hydrocortisone group had a shorter duration of the initial episode of mechanical ventilation,29\n603,RENAL-REPLACEMENT THERAPY,HYDROCORTISONE GROUP,The rate of use of renal-replacement therapy was monitored in the hydrocortisone group,29\n899,ACUTE RESPIRATORY DISTRESS SYNDROME,HYDROCORTISONE GROUP,Some patients in the hydrocortisone group received corticosteroids for acute respiratory distress syndrome,29\n770,UNITED KINGDOM,HYDROCORTISONE GROUP,The United Kingdom was one of the countries where patients were enrolled in the hydrocortisone group,28\n825,ADVERSE EVENTS,HYDROCORTISONE GROUP,The hydrocortisone group experienced a higher percentage of adverse events compared to the placebo group,27\n464,DENMARK,HYDROCORTISONE GROUP,Denmark was one of the countries where patients were enrolled in the hydrocortisone group,27\n655,SAUDI ARABIA,HYDROCORTISONE GROUP,Saudi Arabia was one of the countries where patients were enrolled in the hydrocortisone group,27\n994,HYDROCORTISONE GROUP,ANNANE STUDY,The Annane study reported different outcomes compared to the hydrocortisone group in the current study,26\n992,HYDROCORTISONE GROUP,CORTICOTROPIN,The HYDROCORTISONE GROUP consisted of patients who were evaluated for their response to CORTICOTROPIN. This group included both patients who responded and those who did not respond to corticotropin. The study specifically assessed the hydrocortisone group's response to corticotropin to understand the variability in patient reactions.,26\n995,HYDROCORTISONE GROUP,CLINICAL EVALUATION COMMITTEE,The committee evaluated the appropriateness of antimicrobial therapy for the hydrocortisone group,25\n880,ETOMIDATE,HYDROCORTISONE GROUP,\"In the hydrocortisone group, some patients received etomidate prior to their entry into the study. This administration of etomidate occurred before the randomization process for these patients.\",25\n989,HYDROCORTISONE GROUP,BLOOD TRANSFUSION,Fewer patients in the hydrocortisone group received a blood transfusion compared to the placebo group,24\n990,HYDROCORTISONE GROUP,NEW-ONSET BACTEREMIA,The rate of new-onset bacteremia was tracked in the hydrocortisone group,24\n991,HYDROCORTISONE GROUP,NEW-ONSET FUNGEMIA,The rate of new-onset fungemia was tracked in the hydrocortisone group,24\n993,HYDROCORTISONE GROUP,REVERSAL OF SHOCK,Patients in the hydrocortisone group experienced a shorter time to reversal of shock compared to the placebo group,24\n425,CISATRACURIUM GROUP,SUPPLEMENTARY APPENDIX,The Supplementary Appendix contains additional data and figures related to the cisatracurium group,20\n463,DENMARK,SEPTIC SHOCK TRIAL,The Septic Shock Trial was conducted in Denmark,19\n532,INVESTIGATORS,ADVERSE EVENTS,Investigators recorded adverse events to assess safety during the study,17\n858,CORTICUS STUDY,CORTICOTROPIN,Corticotropin tests were used to assess patient response in the CORTICUS study,16\n454,TRISS,DENMARK,The TRISS trial was conducted in Denmark,16\n856,CORTICUS STUDY,CLINICAL EVALUATION COMMITTEE,The committee assessed antiinfective treatments in the CORTICUS study,15\n462,DENMARK,ADRENAL TRIAL,The ADRENAL trial was conducted in Denmark,12\n209,FLUDROCORTISONE,ANNANE STUDY,Fludrocortisone was used in the Annane study to treat patients,11\n299,CORTICOSTEROID GROUP,SAFETY MONITORING BOARD,The safety monitoring board oversees the safety and efficacy of treatments in the corticosteroid group during the clinical trial,8\n826,ADVERSE EVENTS,STATISTICAL ANALYSIS,Statistical analysis included the evaluation of adverse events reported during the study,7\n1017,ANNANE STUDY,52 ICUS IN NINE COUNTRIES,The Annane study's findings on etomidate were compared with data from the 52 ICUs,6\n424,CISATRACURIUM GROUP,COX REGRESSION MODEL,The Cox regression model was used to analyze the hazard ratio for death in the cisatracurium group,6\n877,CIRCI,ETOMIDATE,Etomidate administration is linked to a higher risk of CIRCI,6\n\n\nThe report should include the following sections:\n\n- TITLE: community's name that represents its key entities - title should be short but specific. When possible, include representative named entities in the title.\n- SUMMARY: An executive summary of the community's overall structure, how its entities are related to each other, and significant information associated with its entities.\n- IMPACT SEVERITY RATING: a float score between 0-10 that represents the severity of IMPACT posed by entities within the community.  IMPACT is the scored importance of a community.\n- RATING EXPLANATION: Give a single sentence explanation of the IMPACT severity rating.\n- DETAILED FINDINGS: A list of 5-10 key insights about the community. Each insight should have a short summary followed by multiple paragraphs of explanatory text grounded according to the grounding rules below. Be comprehensive.\n\nReturn output as a well-formed JSON-formatted string with the following format:\n    {{\n        \"title\": <report_title>,\n        \"summary\": <executive_summary>,\n        \"rating\": <impact_severity_rating>,\n        \"rating_explanation\": <rating_explanation>,\n        \"findings\": [\n            {{\n                \"summary\":<insight_1_summary>,\n                \"explanation\": <insight_1_explanation>\n            }},\n            {{\n                \"summary\":<insight_2_summary>,\n                \"explanation\": <insight_2_explanation>\n            }}\n        ]\n    }}\n\n# Grounding Rules\n\nPoints supported by data should list their data references as follows:\n\n\"This is an example sentence supported by multiple data references [Data: <dataset name> (record ids); <dataset name> (record ids)].\"\n\nDo not list more than 5 record ids in a single reference. Instead, list the top 5 most relevant record ids and add \"+more\" to indicate that there are more.\n\nFor example:\n\"Person X is the owner of Company Y and subject to many allegations of wrongdoing [Data: Reports (1), Entities (5, 7); Relationships (23); Claims (7, 2, 34, 64, 46, +more)].\"\n\nwhere 1, 5, 7, 23, 2, 34, 46, and 64 represent the id (not the index) of the relevant data record.\n\nDo not include information where the supporting evidence for it is not provided.\n\nOutput:", "parameters": {"model": "gpt-4o", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 2000, "n": 1}, "history": null}